Skip to content

Based on the 'Hu-Chang' theory and TGF-beta/Smad pathway toto explore the impact of different cryoablation ranges of lung cancer on the tumor immune microenvironment

Based on the 'Hu-Chang' theory and TGF-beta/Smad pathway toto explore the impact of different cryoablation ranges of lung cancer on the tumor immune microenvironment

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2000004114
Enrollment
Unknown
Registered
2020-09-24
Start date
2020-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Sponsors

Dongfang Hospital Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Aged >=18 years old; (2) Non-small cell lung cancer diagnosed by cytology or histopathology; (3) According to the eighth edition of the TNM staging system for lung cancer published by the International Association for the Study of Lung Cancer (IASLC), it is classified as stage IIIb or stage IV; (4) There is at least one cryoablation lesion with a diameter of 3cm3 months; (7) No history of combined immune-related diseases or other tumors. (8) Volunteer to participate and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Neutrophil count10x10^9/L, platelet2.5 times the upper limit of the normal value in the absence of liver metastasis, or 5 times the upper limit of the reference range of normal value in the case of liver metastasis; (7) Malignant pleural effusion, pericardial effusion or abdominal effusion that is difficult to control; (8) Pregnant or lactating women; (9) HBV or HCV antibody positive; (10) HIV antibody positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.

Design outcomes

Primary

MeasureTime frame
CD4+T content;Treg content;Treg/CD4+T;TGF-beta 1 content;

Secondary

MeasureTime frame
Overall survival, postoperative survival, and progression-free survival of patients with different ranges of cold ablation;The incidence of adverse reactions in patients with different cold ablation ranges;Quality of life of patients with different cold ablation ranges;

Countries

China

Contacts

Public ContactLi Quanwang

Dongfang Hospital Beijing University of Chinese Medicine

quanwangli@126.com+86 13691371560

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026